GEN-MKT-18-7897-A
Oct 15, 2019 | Blogs, Food / Beverage | 0 comments
One question I get asked a lot when it comes to cannabis, specifically regarding marijuana and hemp analysis, is: There are so many techniques to choose from, how do I know which one is best?
I can’t emphasize enough that the Cannabis sativa plant has a complex biological profile with hundreds of chemical entities at varying concentrations. These include both cannabidiol (CBD) and tetrahydrocannabinol (THC).
Because of the complexity of the samples, cannabis labs should consider employing an instrument system that can handle multiple workflows, such as those for potency analysis, pesticide testing, mycotoxin analysis and terpenes profiling. The system also needs to isolate and identify as many compounds as possible and to detect very low concentrations (in the parts per million or parts per billion range).
Before I continue, I should say that there is no perfect method for cannabis testing. Different technologies can impact the quality of your data. One approach can be more effective than another. It depends on the needs of your laboratory. Nevertheless, the characteristics of an ideal analytical technique remain the same: high sensitivity, selectivity, and specificity.
Let’s explore well-known techniques used to analyze marijuana and hemp for pesticides, potency, mycotoxins and terpenes.
Sample separation strategies
Quantitative methods
So, my answer to the original question is that the best method involves using HPLC with a dual-detector combination of UV and tandem mass spectrometry (MS/MS) to analyze cannabinoids. It is a highly effective approach. Check out this technical note our team put together that demonstrates this approach to quantifying cannabinoids in marijuana and hemp.
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
CE‑SDS remains a cornerstone assay for characterizing fragmentation, aggregation, and product‑related impurities in therapeutic proteins. UV detection has been the long‑standing standard. However, it frequently struggles with baseline noise, limited sensitivity for minor fragments, and subjective integration.
Posted by
You must be logged in to post a comment.
Share this post with your network